Meet Fernando

54-year-old journalist and father of 3 who recently moved his family across the country to start a new job.

I thought the weight loss was stress from the move. I was shocked when they said it was kidney cancer. I just want to be here to care for my family—I do everything for them.”

MEDICAL HISTORY: Presented with rapid weight loss and lower back pain

INITIAL DIAGNOSIS: Metastatic renal cell carcinoma (RCC) with a clear cell histology; scheduled for laparoscopic nephrectomy


  • RCC is metastatic and Fernando is treatment naïve
  • ECOG performance status: 0
  • MSKCC risk: favorable
  • Karnofsky performance status (KPS): 90% with minor signs of disease

In COMPARZ, VOTRIENT demonstrated efficacy across a wide range of patients1,2:

85% of patients had a favorable or intermediate MSKCC risk

75% of patients had a 90 or 100 KPS
Patient age ranged from 18 to 88 years

When choosing first-line treatment, what therapy do you consider?

Hypothetical patient case study.

References: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.